Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CTI BioPharma Corp. (NASDAQ: CTIC).

Full DD Report for CTIC

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTIC)

CTI BioPharma's (CTIC) CEO Adam Craig on Q1 2018 Results - Earnings Call Transcript
CTI BioPharma Corp. (CTIC) Q1 2018 Earnings Conference Call May 3, 2018 16:30 ET Executives Tricia Truehart - Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer Analysts Gill ...
Source: SeekingAlpha
Date: May, 03 2018 22:48
CTI BioPharma beats by $0.02, beats on revenue
CTI BioPharma (NASDAQ: CTIC ): Q1 EPS of -$0.08 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:08
CTI BioPharma Reports First Quarter 2018 Financial Results
SEATTLE , May 3, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the first quarter ended March 31, 2018 . In March 2018 , results from the Phase 3 PERSIST-2 clinical trial of pacritinib were published online in JAMA Oncology . The randomize...
Source: PR Newswire
Date: May, 03 2018 16:01
CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018
SEATTLE , April 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2018 financial results on Thursday, May 3, 2018, after the close of the U.S. financial markets. Following the announ...
Source: PR Newswire
Date: April, 26 2018 16:05
We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers
Janssen has removed or omitted imetelstat from key presentation materials We believe Geron (GERN) bulls are missing a key piece of evidence that suggests to us that Janssen (JNJ) is likely to terminate its licensing agreement for imetelstat. In every Johnson & Johnson (Janssen’...
Source: SeekingAlpha
Date: April, 26 2018 08:30
Seeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In Myelofibrosis
We have published an investment thesis on four biotech companies thus far; three of which have generated exceptional returns ( SBBP, INSM, EDGE) . We were recently interviewed by Seeking Alpha where we shared a brief long thesis for CTI BioPharma ( CTIC ). This article constitutes an in-...
Source: SeekingAlpha
Date: March, 27 2018 11:52
SA Interview: Biotechnology Investing With Juggernaut Capital
Feature interview Juggernaut Capital is a private long/short equity fund focused on supporting innovation in life sciences. Notable calls include a bullish thesis on Strongbridge Biopharma (SBBP), bullish thesis on Insmed (INSM), and bullish thesis on Edge Therapeutics (EDGE). We e...
Source: SeekingAlpha
Date: March, 18 2018 07:30
Wired News - CTI BioPharma's Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
Stock Monitor: Fate Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC ). If you want access to this report all you need to do is sign up now by clicking th...
Source: ACCESSWIRE IA
Date: March, 13 2018 07:40
Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC
Analysis of top Seeking Alpha coverage: Immuron Today, we will discuss Immuron ( IMRN ) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in ...
Source: SeekingAlpha
Date: March, 10 2018 08:00
Late-stage data on CTI's pacritinib published in JAMA Oncology
CTI BioPharma (NASDAQ: CTIC ) announces that results from the Phase 3 PERSIST-2 study evaluating JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia have been published online in JAMA Oncology . More news on: CTI BioPharma Corp., Healthcare stocks news, R...
Source: SeekingAlpha
Date: March, 09 2018 07:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-141.981.9452.011.91154,787
2018-08-131.951.972.031.86313,432
2018-08-102.081.9652.09991.95820,721
2018-08-092.162.132.212.11314,085
2018-08-082.242.1252.272.11592,133

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1419,46794,41820.6179Cover
2018-08-1328,161162,71217.3073Cover
2018-08-10143,868399,94835.9717Short
2018-08-0960,170225,53326.6790Cover
2018-08-08142,884414,50634.4709Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTIC.


About CTI BioPharma Corp. (NASDAQ: CTIC)

Logo for CTI BioPharma Corp. (NASDAQ: CTIC)

Not available

 

Contact Information

 

 

Current Management

  • James A. Bianco / President, CEO
  • Louis Bianco / CFO

Current Share Structure

  • Market Cap: $241,182,785 - 05/15/2018
  • Issue and Outstanding: 57,976,631 - 04/26/2018

 


Recent Filings from (NASDAQ: CTIC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: February, 20 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (NASDAQ: CTIC)

Daily Technical Chart for (NASDAQ: CTIC)


Stay tuned for daily updates and more on (NASDAQ: CTIC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTIC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTIC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CTIC and does not buy, sell, or trade any shares of CTIC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/